Mark Crotty

Mark Crotty serves as Executive Chair of LumaCina, leading the company's long-term strategic direction and platform development. He provides continuity and oversight as the business expands its sterile injectable portfolio and international footprint.

Crotty is a highly regarded leader with significant experience at the executive and Board level, in Australia, Europe and New Zealand, across multiple blue-chip multinational healthcare companies including Pfizer, Hospira and Smith and Nephew. Mark was globally recognized as a leader in innovation at Pfizer, where he demonstrated visionary leadership with uncompromising commercial focus and deep understanding of industry trends and dynamics. He is recognized for transforming businesses and building high performing organizations, stemming from strong vision with innovative and brave strategies.

Crotty studied at the University of Waikato. He is not afraid to take on the industry status quo and significantly change the trajectory of business growth.

Career history

• Executive Chair, LumaCina (Bridgewest Group)
• Senior leadership roles at Pfizer, including Pfizer Ireland and Pfizer Australia
• Executive positions at Hospira
• Senior leadership at Smith & Nephew plc
• Director at Crotty Laxon Pty Ltd

What Mark Crotty could bring to his Executive Chair role at LumaCina: Drawing on his extensive background driving innovation and transformation at major pharmaceutical giants, Crotty is positioned to architect LumaCina's evolution as an independent sterile injectable supplier. His recognition for innovation at Pfizer, combined with his track record for building high-performing organizations and reshaping business trajectories, suggests he can scale LumaCina's portfolio expansion and international market penetration while maintaining the strategic continuity the Bridgewest portfolio requires during periods of leadership transition.